| Indicators | Browse All

Cerus Corporation (CERS)

Healthcare | Medical Devices | Concord, United States | NasdaqGM
2.65 USD -0.07 (-2.574%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 2.65

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 2:59 a.m. EDT

The investment case for Cerus is currently broken by a severe disconnect between its deteriorating fundamentals and its market capitalization. While the company recently beat quarterly revenue, the immediate reaction was a 10% drop as management lowered full-year guidance, confirming that the market views this as a continuation of a long-term decline rather than a turnaround. The price trajectory over the last nine years is catastrophic, down 81%, with the most recent annual performance also negative. This is not a value opportunity; it is a business failing to generate the returns required to sustain its valuation, resulting in negative equity metrics and a negative return on assets. Short-term, the stock is trapped in a downtrend, hovering near its 200-day moving average but lacking the volume or catalysts needed to break out. The options market agrees, with heavy put writing at lower strikes indicating a floor is being tested rather than a bounce being anticipated. There is no dividend to provide income, and the balance sheet shows signs of stress with debt exceeding cash reserves. Despite a 'strong buy' analyst recommendation and a target price nearly double the current level, these figures appear to be based on a hope for a successful product launch or a one-time event rather than the current operational reality. Until the company demonstrates sustained profitability and a reversal in the multi-year price trend, the risk-reward profile remains heavily skewed against the buyer. The current price reflects a desperate attempt to find a bottom in a secular decline.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.100046
MSTL0.101316
AutoETS0.101891
AutoARIMA0.102680

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 34%
H-stat 8.67
Ljung-Box p 0.000
Jarque-Bera p 0.127
Excess Kurtosis -0.28
Attribute Value
Sector Healthcare
Debt to Equity Ratio 108.604
Revenue per Share 1.138
Market Cap 534,040,992
Forward P/E -530.00
Beta 1.77
Profit Margins -3.06%
Website https://www.cerus.com

As of Aug. 22, 2026, 2:59 a.m. EDT: Speculators are positioning for a continued grind lower, evidenced by massive open interest in out-of-the-money puts (strikes 1.5 and 2.0) expiring in late 2026 and early 2027. Call activity is concentrated at strikes significantly above the current price (4.0), suggesting a speculative 'lottery ticket' mentality rather than a conviction trade for a near-term recovery. The skew in implied volatility further highlights the market's pricing of downside risk over upside potential.


Info Dump

Attribute Value
52 Week Change 1.1417322
Address1 1,220 Concord Avenue
Address2 Suite 600
All Time High 81.875
All Time Low 0.55
Ask 2.76
Ask Size 2
Audit Risk 6
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 1,907,420
Average Daily Volume3 Month 2,667,977
Average Volume 2,667,977
Average Volume10Days 1,907,420
Beta 1.77
Bid 2.09
Bid Size 2
Board Risk 4
Book Value 0.348
City Concord
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 5
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.65
Current Ratio 1.834
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 2.73
Day Low 2.63
Debt To Equity 108.604
Earnings Call Timestamp End 1,785,443,400
Earnings Call Timestamp Start 1,785,443,400
Earnings Timestamp 1,785,441,600
Earnings Timestamp End 1,793,908,800
Earnings Timestamp Start 1,793,908,800
Ebitda 66,000
Ebitda Margins 0.00029999999
Enterprise To Ebitda 8,413.136
Enterprise To Revenue 2.506
Enterprise Value 555,267,008
Eps Current Year -0.045
Eps Forward -0.005
Eps Trailing Twelve Months -0.03
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.8296
Fifty Day Average Change -0.1796
Fifty Day Average Change Percent -0.06347187
Fifty Two Week Change Percent 114.17322
Fifty Two Week High 3.47
Fifty Two Week High Change -0.81999993
Fifty Two Week High Change Percent -0.23631121
Fifty Two Week Low 1.17
Fifty Two Week Low Change 1.4800001
Fifty Two Week Low Change Percent 1.2649574
Fifty Two Week Range 1.17 - 3.47
Financial Currency USD
First Trade Date Milliseconds 854,721,000,000
Float Shares 195,348,160
Forward Eps -0.005
Forward P E -530.00006
Free Cashflow 875,250
Full Exchange Name NasdaqGM
Full Time Employees 261
Fullday Change -0.0699999
Fullday Change Percent -2.57353
Fullday Price 2.65
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.52049
Gross Profits 115,315,000
Has Pre Post Market Data 1
Held Percent Insiders 0.036140002
Held Percent Institutions 0.73333
Implied Shares Outstanding 201,524,898
Industry Medical Devices
Industry Disp Medical Devices
Industry Key medical-devices
Ir Website http://www.cerus.com/Investors/Investor-Overview/default.aspx
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.
Long Name Cerus Corporation
Market us_market
Market Cap 534,040,992
Market State CLOSED
Max Age 86,400
Message Board Id finmb_26334
Most Recent Quarter 1,782,777,600
Net Income To Common -6,783,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 549,155,347
Number Of Analyst Opinions 3
Open 2.7
Operating Cashflow 2,417,000
Operating Margins -0.03235
Overall Risk 6
Payout Ratio 0.0
Phone 925 288 6000
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 2.65
Post Market Time 1,787,959,805
Previous Close 2.72
Price Eps Current Year -58.88889
Price Hint 4
Price To Book 7.614943
Price To Sales Trailing12 Months 2.4104652
Profit Margins -0.030620001
Quick Ratio 1.017
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.0699999
Regular Market Change Percent -2.57353
Regular Market Day High 2.73
Regular Market Day Low 2.63
Regular Market Day Range 2.63 - 2.73
Regular Market Open 2.7
Regular Market Previous Close 2.72
Regular Market Price 2.65
Regular Market Time 1,787,947,201
Regular Market Volume 1,683,557
Return On Assets -0.00483
Return On Equity -0.10772
Revenue Growth 0.095
Revenue Per Share 1.138
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 201,524,898
Shares Percent Shares Out 0.086
Shares Short 17,330,786
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 13,688,689
Short Name Cerus Corporation
Short Percent Of Float 0.088599995
Short Ratio 6.01
Source Interval 15
State CA
Symbol CERS
Target High Price 5.0
Target Low Price 4.0
Target Mean Price 4.66667
Target Median Price 5.0
Total Cash 56,264,000
Total Cash Per Share 0.279
Total Debt 76,799,000
Total Revenue 221,551,008
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.03
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.3379
Two Hundred Day Average Change 0.31210017
Two Hundred Day Average Change Percent 0.13349596
Type Disp Equity
Volume 1,683,557
Website https://www.cerus.com
Zip 94,520